证券代码：688307 证券简称：中润光学 公告编号：2023-017 1 制定了《嘉兴中润光学科技股份有限公司募集资金管理制度》，对募集资金的存 储、使用及管理等方面做出了明确的规定。 公司对募集资金实行专户存储，在银行设立募集资金专户，并连同保荐机构 国信证券股份有限公司与中国农业银行股份有限公司嘉兴科技支行、招商银行股 份有限公司嘉兴分行营业部、杭州银行股份有限公司嘉兴分行分别签订了《募集 资金专户存储三方监管协议》，并对募集资金的使用实施严格审批，以保证专款 专用。募集资金专项账户的开立和存储情况如下： 嘉兴中润光学科技股份有限公司 关于部分募集资金专户销户完成的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 嘉兴中润光学科技股份有限公司（以下简称"公司"）首次公开发行股票募 集资金按照相关法律、法规和规范性文件的规定在银行开立了募集资金专用账 户。近日公司办理完成了对部分募集资金专用账户的注销手续，具体情况如下： 一、募集资金基本情况 根据中国证券监督管理委员会于 2022 年 12 月 5 日签发的《关于 ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥67,334,084.36, representing a year-on-year increase of 7.55%[4] - The net profit attributable to shareholders was a loss of ¥947,435.82, a decrease of 165.74% compared to the same period last year[4] - The net cash flow from operating activities was negative at ¥17,831,345.30, reflecting a decline of 225.31% year-on-year[4] - Total operating revenue for Q1 2023 was CNY 67,334,084.36, an increase of 7.0% compared to CNY 62,609,762.38 in Q1 2022[18] - Net profit for Q1 2023 was a loss of CNY 708,725.43, compared to a loss of CNY 387,570.58 in Q1 2022[19] - The company reported a net cash outflow from operating activities of CNY -17,831,345.30 in Q1 2023, down from a net inflow of CNY 14,230,298.47 in Q1 2022[21] Assets and Liabilities - Total assets increased to ¥965,059,374.38, marking a growth of 66.27% from the end of the previous year[5] - The total liabilities amounted to CNY 147,556,442.28, a decrease from CNY 209,291,001.90 in the previous year[16] - The total current liabilities decreased to ¥97,891,892.93 from ¥173,978,411.23, a reduction of approximately 43.6%[15] - The company's total liabilities decreased significantly, indicating improved financial health and reduced debt levels[15] Shareholder Information - The equity attributable to shareholders rose to ¥814,012,436.36, an increase of 121.58% compared to the previous year-end[5] - The total equity attributable to shareholders of the parent company increased to CNY 814,012,436.36 from CNY 367,360,542.42[16] - The total number of ordinary shareholders at the end of the reporting period was 8,094[10] - The largest shareholder, Zhang Pinghua, holds 24,561,042 shares, representing 27.91% of the total shares[10] Cash Flow and Financing Activities - The company's cash and cash equivalents amounted to ¥414,911,699.86, compared to ¥21,719,666.02 in the previous year, indicating a substantial increase of approximately 1,804.5%[14] - The net cash increase from financing activities was $431,492,647.73, a significant increase compared to $7,457,702.92 in the previous period[22] - Total cash and cash equivalents at the end of the period reached $409,244,605.47, up from $29,082,399.08 in the previous period[22] - Cash inflow from financing activities totaled $490,315,200.00, compared to $13,000,000.00 in the previous period[22] - Cash outflow for financing activities was $58,822,552.27, significantly higher than $5,542,297.08 in the previous period[22] Research and Development - Research and development expenses totaled ¥9,348,062.73, accounting for 13.88% of operating revenue, a decrease of 2.21 percentage points year-on-year[4] - Research and development expenses for Q1 2023 were CNY 9,348,062.73, slightly down from CNY 10,075,957.92 in Q1 2022[18] Inventory and Receivables - Accounts receivable decreased to ¥54,253,148.90 from ¥75,403,097.84, representing a decline of about 28.0%[14] - The company’s inventory slightly decreased to ¥102,746,591.45 from ¥103,197,808.41, a decrease of about 0.4%[14] Other Financial Metrics - The basic and diluted earnings per share were both reported at -¥0.01[4] - The company reported non-recurring gains of ¥234,789.45, primarily from government subsidies and other occasional income[7] - The company’s deferred income tax liabilities were CNY 39,094.67, a slight decrease from CNY 40,140.56 in the previous year[16] - The company experienced a foreign exchange impact of -$245,165.99 on cash and cash equivalents[22] Strategic Focus - The company is focusing on expanding its market presence and enhancing its product offerings through new technology development and strategic initiatives[12] Reporting Information - The report was released on April 28, 2023, by the board of directors of Jiaxing Zhongrun Optical Technology Co., Ltd.[22]

Financial Performance - The company plans to distribute a cash dividend of RMB 2 per 10 shares, totaling RMB 17.6 million, which represents 42.81% of the net profit attributable to shareholders [6]. - The company has not achieved profitability since its listing, indicating ongoing financial challenges [4]. - Huawei reported a significant increase in revenue, reaching CNY 636.8 billion, representing a year-over-year growth of 10.4% [13]. - The company achieved a net profit margin of 9.8%, with net profits amounting to CNY 62.3 billion, up 5.2% from the previous year [13]. - The company's operating revenue for 2022 was CNY 404.01 million, representing a year-on-year growth of 1.89% [23]. - The net profit attributable to shareholders for 2022 was CNY 41.12 million, an increase of 14.37% compared to the previous year [25]. - The net profit after deducting non-recurring gains and losses was CNY 32.87 million, up 2.22% year-on-year [23]. - The company's total assets at the end of 2022 were CNY 580.42 million, a 1.90% increase from the previous year [23]. - The return on equity (ROE) for 2022 was 11.84%, an increase of 0.56 percentage points from 2021 [24]. - The company reported a basic earnings per share of CNY 0.62, reflecting a 14.81% increase from the previous year [24]. Research and Development - Huawei plans to invest CNY 100 billion in R&D over the next five years, focusing on AI and 5G technologies [14]. - Research and development expenses accounted for 10.07% of operating revenue, up from 8.36% in 2021 [24]. - The company invested 40.6829 million RMB in R&D, accounting for 10.07% of operating revenue, with a year-on-year increase of 22.75% [39]. - The company applied for 33 patents during the year, including 32 invention patents, and received 37 patents, of which 25 were invention patents [39]. - The company has developed a dual-light fusion imaging and sensor focusing technology that enables full-color imaging in low-light conditions, significantly improving image quality [76]. - The company is focused on enhancing optical lens performance, including improving resolution and infrared coherence, to meet market demands [92]. Market Strategy and Expansion - The company aims to expand its market presence in Europe and North America, targeting a 20% increase in market share by 2025 [14]. - The company plans to continue expanding in emerging fields such as machine vision, despite some slowdown in downstream projects in the digital security sector [25]. - The company is actively pursuing mergers and acquisitions to enhance its competitive position in the industry [177]. - The company is expanding into emerging markets such as machine vision and other segments of digital security, but faces uncertainties in market development [107]. - The company plans to launch a new short-focus projection lens using a glass-plastic hybrid design, targeting the laser TV market [94]. Governance and Compliance - The company has not violated decision-making procedures for external guarantees [9]. - The company has not faced any issues with a majority of directors being unable to ensure the accuracy of the annual report [9]. - The company does not have any special arrangements for corporate governance [7]. - The company strictly adheres to the requirements of the Company Law and Securities Law of the People's Republic of China, continuously improving its governance structure [163]. - The board of directors has approved the profit distribution plan, pending approval from the annual general meeting [6]. - The company has established a differentiated compensation structure based on job responsibilities and performance, ensuring fairness and competitiveness in employee remuneration [194]. Operational Efficiency - The company has automated the production and testing of zoom lenses, significantly improving production efficiency and supporting the industrial application of precision optical lenses [102]. - The company has implemented strict quality control measures across all business processes to ensure product quality and service standards [102]. - The company has established a robust design review system and product database to support continuous innovation and technical breakthroughs in product development [48]. - The company has implemented a high-precision optical component and lens assembly testing technology, achieving a product consistency rate of over 98% in complex zoom group assembly within 30 seconds [81]. Customer and Market Dynamics - The first major customer, Dahua Technology, accounted for 41.43% of total revenue, while the top five customers contributed 59.70%, highlighting a high customer concentration risk [108]. - The company has established a strong customer base, including major clients like Huawei and DJI, which supports sustained business growth and creates industry barriers [101]. - The company reported a significant increase of 840.91% in accounts receivable, amounting to 20.38 million yuan, due to an increase in bank acceptance bills received [142]. Future Outlook - The company provided a positive outlook for the next quarter, projecting revenue growth of 20% to $180 million [172]. - The company aims to improve its performance metrics through enhanced operational strategies and market analysis [170]. - Future outlook includes potential market expansion and new product development strategies [170]. - The company plans to strengthen partnerships with strategic clients and enhance customer development to drive high-end product recognition [156].

股票简称：中润光学 股票代码：688307 嘉兴中润光学科技股份有限公司 （浙江省嘉兴市秀洲区高照街道陶泾路 188 号） 首次公开发行股票科创板上市公告书 保荐机构（主承销商） （注册地址：深圳市罗湖区红岭中路 1012 号国信证券大厦十六至二十六层） 二零二三年二月十五日 声明及承诺 本公司及全体董事、监事、高级管理人员保证上市公告书所披露信息的真实、 准确、完整，承诺上市公告书不存在虚假记载、误导性陈述或重大遗漏，并依法 承担法律责任。 上海证券交易所、有关政府机关对本公司股票上市及有关事项的意见，均不 表明对本公司的任何保证。本公司提醒广大投资者认真阅读刊载于上海证券交易 所网站（http：//www.sse.com.cn）的本公司招股说明书"风险因素"章节的内容， 注意风险，审慎决策，理性投资。 本公司提醒广大投资者注意，凡本上市公告书未涉及的有关内容，请投资者 查阅本公司招股说明书全文。 如无特别说明，本上市公告书中的简称或名词的释义与本公司招股说明书中 的相同。 二、新股上市初期的投资风险提示 嘉兴中润光学科技股份有限公司（以下简称"中润光学"、"发行人"、"公 司"或"本公司"）股票将于 20 ...

特别提示：本次股票发行后拟在科创板市场上市，该市场具有较高的投资风险。科创 板公司具有研发投入大、经营风险高、业绩不稳定、退市风险高等特点，投资者面临 较大的市场风险。投资者应充分了解科创板市场的投资风险及本公司所披露的风险因 素，审慎作出投资决定。 嘉兴中润光学科技股份有限公司 （浙江省嘉兴市秀洲区高照街道陶泾路 188 号） 首次公开发行股票并在科创板上市 招股说明书 保荐机构（主承销商） （注册地址：深圳市罗湖区红岭中路 1012 号国信证券大厦十六至二十六层） 嘉兴中润光学科技股份有限公司 首次公开发行股票并在科创板上市招股说明书 声明及承诺 中国证监会、交易所对本次发行所作的任何决定或意见，均不表明其对注 册申请文件及所披露信息的真实性、准确性、完整性作出保证，也不表明其对 发行人的盈利能力、投资价值或者对投资者的收益作出实质性判断或保证。任 何与之相反的声明均属虚假不实陈述。 根据《证券法》的规定，股票依法发行后，发行人经营与收益的变化，由 发行人自行负责；投资者自主判断发行人的投资价值，自主作出投资决策，自 行承担股票依法发行后因发行人经营与收益变化或者股票价格变动引致的投资 风险。 发行人及全 ...

嘉兴中润光学科技股份有限公司 首次公开发行股票并在科创板上市 发行结果公告 保荐机构（主承销商）：国信证券股份有限公司 特别提示 嘉兴中润光学科技股份有限公司（以下简称"中润光学"、"发行人"或"公司"） 首次公开发行不超过 2,200.00 万股人民币普通股（A 股）（以下简称"本次发行"） 的申请已经上海证券交易所科创板股票上市委员会委员审议通过，并已经中国证 券监督管理委员会（以下简称"中国证监会"）证监许可〔2022〕3064 号文同意注 册。本次发行的保荐机构（主承销商）为国信证券股份有限公司（以下简称"国 信证券"或"保荐机构（主承销商）"）。发行人的股票简称为"中润光学"，股票代 码为"688307"。 本次发行采用向战略投资者定向配售（以下简称"战略配售"）、网下向符合 条件的网下投资者询价配售（以下简称"网下发行"）和网上向持有上海市场非限 售 A 股股份和非限售存托凭证市值的社会公众投资者定价发行（以下简称"网上 发行"）相结合的方式进行。发行人和保荐机构（主承销商）综合考虑发行人基 本面、本次公开发行的股份数量、发行人所处行业、可比上市公司估值水平、市 场情况、募集资金需求以及承销风险等 ...

嘉兴中润光学科技股份有限公司 首次公开发行股票并在科创板上市 发行公告 保荐机构（主承销商）：国信证券股份有限公司 扫描二维码查阅公告全文 重要提示 | 发行人基本情况 | | | | | --- | --- | --- | --- | | 公司全称 | 嘉兴中润光学科技 | 证券简称 | 中润光学 | | 股份有限公司 | | | | | 证券代码/网下申购 | 688307 | 网上申购代码 | 787307 | | 代码 | | | | | 网下申购简称 | 中润光学 | 网上申购简称 | 中润申购 | | 本次发行基本情况 | | | | | 定价方式 | 网下初步询价直接 确定发行价格，网下 | 本次发行数量（万 | 2,200.00 | | 不再进行累计投标 | | 股） | | | 询价 | | | | | 发行后总股本（万 股） | 8,800.00 | 本次发行数量占发 行 后 总 股 本 比 例 | 25.00 | | （%） | | | | | 高价剔除比例（%） | 1.0057 | 四数孰低值（元/股） | 23.9477 | | 本次发行价格（元/ | 23.88 | 本次发行价格 ...

特别提示：本次股票发行后拟在科创板市场上市，该市场具有较高的投资风险。科创 板公司具有研发投入大、经营风险高、业绩不稳定、退市风险高等特点，投资者面临 较大的市场风险。投资者应充分了解科创板市场的投资风险及本公司所披露的风险因 素，审慎作出投资决定。 嘉兴中润光学科技股份有限公司 （浙江省嘉兴市秀洲区高照街道陶泾路 188 号） 首次公开发行股票并在科创板上市 招股意向书 保荐机构（主承销商） （注册地址：深圳市罗湖区红岭中路 1012 号国信证券大厦十六至二十六层） 嘉兴中润光学科技股份有限公司 招股意向书 嘉兴中润光学科技股份有限公司 招股意向书 声明及承诺 中国证监会、交易所对本次发行所作的任何决定或意见，均不表明其对注册 申请文件及所披露信息的真实性、准确性、完整性作出保证，也不表明其对发行 人的盈利能力、投资价值或者对投资者的收益作出实质性判断或保证。任何与之 相反的声明均属虚假不实陈述。 根据《证券法》的规定，股票依法发行后，发行人经营与收益的变化，由发 行人自行负责；投资者自主判断发行人的投资价值，自主作出投资决策，自行承 担股票依法发行后因发行人经营与收益变化或者股票价格变动引致的投资风险。 ...